Last reviewed · How we verify
WF10
WF10 is a stable, diluted solution of dihydroxyethyl disulfide that acts as an immunomodulator and antioxidant to enhance immune function and reduce inflammatory responses.
WF10 is a stable, diluted solution of dihydroxyethyl disulfide that acts as an immunomodulator and antioxidant to enhance immune function and reduce inflammatory responses. Used for Wound healing and tissue repair, Immune dysfunction disorders.
At a glance
| Generic name | WF10 |
|---|---|
| Also known as | Immunokine |
| Sponsor | Oxo Chemie GmbH |
| Drug class | Immunomodulator |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
WF10 works by activating macrophages and enhancing the body's natural immune response while simultaneously reducing oxidative stress and inflammatory mediators. It has been investigated for its ability to modulate immune function in conditions characterized by immune dysfunction or excessive inflammation, particularly in wound healing and tissue repair contexts.
Approved indications
- Wound healing and tissue repair
- Immune dysfunction disorders
Common side effects
Key clinical trials
- Effect of WF10 (TCDO) on HbA1c Values in Diabetic Foot Ulcer Patients (PHASE2)
- PILOT STUDY OF THE EFFICACY AND SAFETY OF WF10 IN SUBJECTS SUFFERING FROM PERSISTENT ALLERGIC RHINITIS (PHASE2)
- A Study to Evaluate the Safety and Effectiveness of WF10 Given to Patients With Late-Stage HIV Disease (PHASE3)
- A Phase I/II Clinical Study of WF 10 IV Solution ( TCDO ) in Patients With HIV Infection (PHASE1)
- A Study of WF 10 IV Solution in Patients With Advanced HIV Disease (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- WF10 CI brief — competitive landscape report
- WF10 updates RSS · CI watch RSS
- Oxo Chemie GmbH portfolio CI